Virtus ETF Advisers LLC Makes New $71,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Virtus ETF Advisers LLC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 20,910 shares of the company’s stock, valued at approximately $71,000.

A number of other large investors have also modified their holdings of XERS. JPMorgan Chase & Co. grew its stake in shares of Xeris Biopharma by 166.2% in the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company’s stock valued at $3,537,000 after buying an additional 651,481 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after buying an additional 500,120 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $1,610,000. AIGH Capital Management LLC grew its stake in shares of Xeris Biopharma by 17.8% in the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock valued at $8,729,000 after buying an additional 389,192 shares in the last quarter. Finally, EAM Investors LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $754,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.56% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on XERS shares. Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Xeris Biopharma Stock Up 2.3 %

NASDAQ:XERS opened at $4.41 on Tuesday. The business’s 50 day moving average is $4.50 and its two-hundred day moving average is $3.76. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.71 and a 52 week high of $6.07. The company has a market cap of $689.66 million, a PE ratio of -9.80 and a beta of 1.37.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.